Advertisement

Search Results

Advertisement



Your search for can matches 13381 pages

Showing 751 - 800


immunotherapy
symptom management

CAR T-Cell Therapy Complications: Comparison of Three Testing Modalities

Magnetic resonance imaging (MRI) and lumbar puncture may not always be necessary for diagnosing and managing a serious neurologic complication associated with chimeric antigen receptor (CAR) T-cell therapy, according to a new study published by Mauget et al in Blood Advances. Findings further...

prostate cancer

Localized Prostate Cancer: Association of PSA Nadir Within 6 Months of Radiotherapy With Outcomes

In a study reported in the Journal of Clinical Oncology, Kwak et al found that prostate-specific antigen (PSA) levels ≥ 0.1 ng/mL within 6 months after completion of radiotherapy were prognostic for poorer outcomes in patients with localized prostate cancer who did or did not also receive...

lymphoma

Mantle Cell Lymphoma: Front-Line Therapy

“The practice of medicine is an art, not a trade….” —Sir William Osler Mantle cell lymphoma (MCL) accounts for approximately 5% to 7% of all lymphomas; the median age of patients with MCL is between 60 and 70 years. This lymphoma is generally considered incurable. Median survival in retrospective...

cardio-oncology
leukemia

Strategies for Cardiovascular Risk Mitigation and Monitoring in Patients With CLL

With a 5-year overall survival of close to 90% in chronic lymphocytic leukemia (CLL), there have been large treatment shifts over the past decade in this disease, which now includes “more disciplines than it did before,” commented medical oncologist Danielle Shafer, DO, of Inova Schar Cancer...

cardio-oncology
lung cancer

Risks of Cardiovascular Disease in Patients Receiving Therapies for Lung Cancer

Managing patients with lung cancer in the current era of an increasing array of systemic treatments has become a complex balancing act of trying to improve outcomes and survival from a cancer perspective while taking the necessary treatment and monitoring steps for cardioprotection. With few...

gastroesophageal cancer
immunotherapy

Liquid Biopsy May Help Predict Outcomes in Patients With Gastroesophageal Cancers Following Immunotherapy

Monitoring circulating tumor DNA (ctDNA) levels with liquid biopsies could help physicians accurately assess treatment responses and predict future prognoses in patients with operable esophageal or gastroesophageal junction cancer receiving an immunotherapy doublet, according to a recent study...

prostate cancer
issues in oncology

Hormonal Therapy Plus SBRT for Advanced Prostate Cancer

Treatment with a short course of intensified hormonal therapy in combination with metastasis-directed stereotactic body radiation therapy (SBRT) may be safe and effective in patients with oligorecurrent and metastatic prostate cancer, according to a recent study published by Nikitas et al in...

gynecologic cancers
supportive care

ChatGPT May Accurately Answer Common Patient Questions Regarding Gynecologic Cancer

The artificial intelligence (AI)-based chatbot ChatGPT version 3.4 may correctly answer a majority of the common genetic counseling questions related to gynecologic oncology, according to new findings presented by Patel et al at the Society of Gynecologic Oncology’s (SGO) 2024 Annual Meeting on...

colorectal cancer
genomics/genetics
issues in oncology

Exploring the Genetic Link Between Colorectal Cancer and Meat Consumption

Researchers have identified two genetic markers that may illuminate the association between red and/or processed meat consumption and the risk of colorectal cancer, according to a novel study published by Stern et al in Cancer Epidemiology, Biomarkers & Prevention. Background Previous studies...

leukemia
lymphoma
immunotherapy

Accelerated Approval Granted to First CAR T-Cell Therapy for Relapsed or Refractory CLL/SLL

On March 14, the U.S. Food and Drug Administration (FDA) granted accelerated approval to lisocabtagene maraleucel (Breyanzi), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy, for the treatment of adults with relapsed or refractory chronic lymphocytic leukemia (CLL) or small...

breast cancer
covid-19

Trends in Breast Cancer Diagnoses During the COVID-19 Pandemic

Investigators may have identified a decrease in newly diagnosed breast cancer cases during the first year of the COVID-19 pandemic, according to a recent study published by Fefferman et al in Cancer Medicine. The findings highlight that breast cancer was not immune to pandemic-related stressors and ...

From a Small Town in Lebanon, a Young Doctor Follows His Passion to an International Career in Cancer Research

Philip A. Salem, MD, Director Emeritus of Cancer Research at St. Luke’s Episcopal Hospital, Houston, was born and reared in Bterram, a village that overlooks the Mediterranean Sea. “I had the most beautiful and blessed childhood, as I lived in a household dominated by a father who believed in the...

cns cancers
immunotherapy

Novel Dual-Target CAR T-Cell Therapy for Recurrent Glioblastoma

Targeting two brain tumor–associated proteins with chimeric antigen receptor (CAR) T-cell therapy may reduce solid tumor growth in patients with recurrent glioblastoma, according to results from a phase I trial published by Bagley et al in Nature Medicine. The findings suggest that the new...

hematologic malignancies
cardio-oncology

Risk Score to Assess Cardiovascular Complications in Hematopoietic Stem Cell Transplant Recipients

A novel tool may help predict the risk of complications following hematopoietic stem cell transplantation and guide the pretransplant process, according to new Scientific Statement published by Hayek et al in Circulation. The findings may also illuminate the contemporary prevalence of...

supportive care
issues in oncology

Collaborative Care Intervention May Benefit Patients With Cancer, Health-Care Systems

Adding specialized mental health support to the treatment plan of patients with cancer may improve their quality of life, lower the risk of cardiovascular disease in family caregivers, and boost cost savings to the health-care system, according to a recent study published by Steel et al in The...

leukemia

Zanubrutinib vs Acalabrutinib in Relapsed or Refractory CLL: New Efficacy Analysis

A new matching adjusted indirect comparison of the efficacy of zanubrutinib vs acalabrutinib in relapsed or refractory chronic lymphocytic leukemia (CLL) based on data from the phase III ALPINE and ASCEND trials was presented by Shadman et al at the 28th Annual International Congress on Hematologic ...

solid tumors
issues in oncology

Worsening Metabolic Syndrome May Increase Cancer Risk

Investigators may have identified a heightened risk of various types of cancers among patients with persistent and worsening metabolic syndrome, according to a recent study published by Deng et al in Cancer. Background Metabolic syndrome encompasses conditions such as high blood pressure, elevated...

breast cancer
issues in oncology

Higher BMI May Be Linked to Complications Following Autologous Breast Reconstruction

Patients with a higher body mass index (BMI) may have a greater risk of overall and specific complications following autologous breast reconstruction, according to a recent study published by Barnes et al in Plastic and Reconstructive Surgery. Background Autologous breast reconstruction—an...

breast cancer
genomics/genetics

ASCO and SSO Publish New Guideline on Germline Testing in Breast Cancer

ASCO in partnership with the Society of Surgical Oncology (SSO) has released a new guideline addressing recommendations in germline testing in patients with breast cancer.1 The guideline provides oncologists with a framework for how to approach germline testing and recommendations for who should be ...

Expert Point of View: Rachid Baz, MD

DREAMM-7, which evaluated belantamab mafodotin-blmf, bortezomib, and dexamethasone (BVd) in relapsed or refractory multiple myeloma, was discussed at the virtual session by Rachid Baz, MD, Myeloma Section Head and Co-Director of the Pentecost Family Myeloma Research Center at Moffitt Cancer Center, ...

multiple myeloma

Benefit of Belantamab Mafodotin–Based Regimen Supported in Multiple Myeloma

Positive results with the use of belantamab mafodotin-blmf in the phase III DREAMM-7 study were presented during the ASCO Plenary Series: February 2024.1 In relapsed or refractory multiple myeloma, DREAMM-7 evaluated the use of the regimen belantamab mafodotin, bortezomib, and dexamethasone (BVd)...

issues in oncology

How The Max Foundation Is Accelerating Equitable Cancer Care Globally

When Pat Garcia-Gonzalez’ stepson, Max, was diagnosed with chronic myeloid leukemia (CML) in 1988 at the age of 14, the Internet was still in its infancy and decades away from the networking resource it has become today. Told that Max would need an allogeneic stem cell transplant to survive, the...

colorectal cancer

Expert Point of View: Aparna R. Parikh, MD

he latest findings for circulating tumor DNA (ctDNA) in colorectal cancer were discussed at the 2024 ASCO Gastrointestinal (GI) Cancers Symposium by Aparna R. Parikh, MD, a gastrointestinal oncologist at Massachusetts General Hospital Cancer Center and Assistant Professor of Medicine at Harvard...

colorectal cancer

Expert Point of View: Alan P. Venook, MD, FASCO

For perspective on CheckMate 8HW, The ASCO Post interviewed Alan P. Venook, MD, FASCO, the Madden Family Distinguished Professor of Medical Oncology and Translational Research at the University of California San Francisco and the Shorenstein Associate Director for Program Development at the Helen...

colorectal cancer

Nivolumab Plus Ipilimumab Improves Progression-Free Survival in First-Line Setting of Metastatic Colorectal Cancer

In the phase III CheckMate 8HW trial, previously untreated patients with microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR) nonresectable or metastatic colorectal cancer derived significant benefit from an immunotherapy doublet, with nivolumab plus ipilimumab reducing the...

solid tumors
genomics/genetics

Inherited Genetic Factors May Influence Risk of Subsequent Cancer Diagnoses in Childhood Cancer Survivors

Investigators have found that common inherited genetic factors capable of predicting cancer risk in the general population may also help to predict childhood cancer survivors who may be at elevated risk of new cancers later in life, according to a recent study published by Gibson et al in Nature...

hematologic malignancies
immunotherapy

Factors Associated With Myeloid Neoplasms Following CAR T-Cell Therapy

In an analysis reported in a research letter in JAMA Oncology, Gurney et al identified factors associated with an increased risk of myeloid neoplasms after chimeric antigen receptor (CAR) T-cell therapy. Study Details Investigators identified adults who received CAR T-cell therapy between June 2016 ...

lung cancer
genomics/genetics
issues in oncology

Could Smoking-Related DNA Changes Reflect Differential Lung Cancer Risks by Race and Ethnicity?

Investigators may have uncovered differential associations between smoking and DNA methylation across various racial and ethnic groups, according to a recent study published by Huang et al in the American Journal of Human Genetics. The findings could lead to the development of new strategies to...

gynecologic cancers
colorectal cancer
bladder cancer
head and neck cancer
genomics/genetics

Can Dual HER2 Blockade Treat More Than Just Breast or Gastric Cancer?

The established dual HER2 blockade of pertuzumab and trastuzumab may be an effective treatment for patients with several types of HER2-amplified cancers, according to a study published by Connolly et al in Clinical Cancer Research. Background HER2 receptors control how cells grow and divide. The...

NCCN Updates Treatment Recommendations for Breast, Colorectal, Lung, and Other Cancers

The National Comprehensive Cancer Network® (NCCN®) is announcing several new updates to the cancer treatment practices listed in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). The evidence-based expert consensus recommendations are the most frequently updated guidelines for...

head and neck cancer

Can HPV ctDNA Guide the Adjuvant Treatment of Oropharyngeal Cancer?

Although liquid biopsies are now helping determine the need for adjuvant therapy in a number of malignancies, they have yet to prove useful in the setting of oropharyngeal carcinoma, according to a prospective pilot study presented at the 2024 Multidisciplinary Head and Neck Cancers Symposium that...

solid tumors
issues in oncology

Impact of Behavioral Health Disorders on Cancer Surgery Outcomes

Investigators may have uncovered new insights into the relationship between behavioral health disorders and cancer surgery outcomes, according to a recent study published by Katayama et al in the Journal of the American College of Surgeons. The findings clarified the need for behavioral health...

prostate cancer
issues in oncology

AUA, ASTRO, SUO Release Clinical Practice Guidelines on Salvage Therapy for Prostate Cancer

The American Urological Association (AUA), in partnership with the American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO), released new clinical practice guidelines on salvage therapy for patients with prostate cancer. These guidelines were reported on by Morgan...

genomics/genetics
issues in oncology

Online Genetic Education Programs May Spur Testing for Patients at Risk for Cancer

Researchers have demonstrated that an online genetic education program may encourage patients with a family history of cancer to undertake genetic testing, according to a recent study published by Rodriguez et al in Gastroenterology. Background Although research has shown that an inherited...

issues in oncology

President’s Cancer Panel Report Highlights Opportunities to Accelerate Progress Toward the National Cancer Plan

A new report from the President’s Cancer Panel offers recommendations in five priority areas to accelerate progress toward implementing the National Cancer Plan and achieving the Biden-Harris Administration’s Cancer Moonshot goal of ending cancer as we know it. The report, delivered to President...

head and neck cancer
issues in oncology

Exposure to Secondhand Smoke During Chemotherapy May Decrease Treatment Efficacy in Patients With Head and Neck Cancer

Researchers have found that exposure to secondhand smoke during treatment with cisplatin may reduce its effectiveness in patients with head and neck cancer, even if they don’t have a history of smoking, according to a recent study published by Sadhasivam et al in the International Journal of...

breast cancer
colorectal cancer
issues in oncology

U.S. Individuals With Incarceration History May Have Lower Likelihood of Undergoing Cancer Screenings

Investigators have found that U.S. individuals with a history of incarceration may have worse access to and receipt of breast cancer and colorectal cancer screenings compared with those without a history of incarceration, according to a recent study published by Zhao et al in JAMA Health Forum....

issues in oncology

Celebrating Advances in Cancer Care and a Look at How AI Is Revolutionizing Oncology

For the third year in a row, more than 250 leaders in cancer care, including cancer center directors, physicians, scientists, ethicists, journalists, public officials, and patient advocates, gathered at the Richard Nixon Presidential Library and Museum in Yorba Linda, California, to attend the...

solid tumors
issues in oncology

Psychological Distress May Contribute to Cancer Treatment Delays

Researchers have found that psychological distress may contribute to delayed cancer treatment, according to a recent study published by Frosch et al in Supportive Care in Cancer. Background Prior research has shown that delays in initiating cancer therapy may be increasing, and these delays can...

breast cancer

Highlights From the 2023 San Antonio Breast Cancer Symposium

Studies presented at the 2023 San Antonio Breast Cancer Symposium (SABCS) significantly moved the needle forward in our treatment of breast cancer. We are increasingly learning how to stratify risk, so we can optimize therapy and minimize our patients’ exposure to treatments that will not be...

breast cancer

Some Patients With Breast Cancer May Safely Avoid Locoregional Irradiation After Neoadjuvant Chemotherapy

It may be possible for some patients with breast cancer to avoid adjuvant regional nodal irradiation safely, according to the results of the NRG Oncology/NSABP B-51/RTOG 1304 clinical trial presented at the 2023 San Antonio Breast Cancer Symposium.1 These findings particularly apply to patients...

breast cancer

IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?

Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...

Expert Point of View: Valentina Guarneri, MD

Invited discussant of the HER2CLIMB-02 trial, Valentina Guarneri, MD, of Padeva Istituto Oncologica Veneto, Italy, hailed these results as important, especially for patients with HER2-positive breast cancer and brain metastases. However, she noted, “HER2CLIMB-02 is not likely to challenge the...

solid tumors
issues in oncology

Families of Men With Subfertility May Have Increased Risk of Several Types of Cancers

Investigators have found that the families of subfertile men may have a higher risk of developing certain types of cancers at younger ages compared with the families of fertile men, according to a recent study published by Ramsay et al in Human Reproduction. Background Previous research has shown...

genomics/genetics

Preventing Cancer Should Not Mean Sacrificing Quality of Life

My family first suspected we might have inherited the BRCA1/2 gene mutation after my father was diagnosed with his third cancer, colorectal cancer, following multiple bouts of squamous cell carcinoma and basal cell carcinoma beginning in his 30s and later prostate cancer. But the high risk of...

breast cancer

IDEA Trial: Might Radiation One Day Be Safely Omitted for Younger, Favorable-Risk, Postmenopausal Patients With Breast Cancer?

Investigators used low recurrence scores on a genomic assay as guidance for selection of favorable-risk patients, and they found most postmenopausal patients (aged 50–69) with stage I hormone receptor–positive breast cancer who omitted adjuvant radiation therapy but continued endocrine therapy for...

gastroesophageal cancer

Evaluating the Use of Perioperative Chemoimmunotherapy in Resectable Gastric and Gastroesophageal Junction Cancers

Updates of two key phase III trials presented at the 2024 ASCO Gastrointestinal Cancers Symposium showed the benefit of adding a checkpoint inhibitor to standard perioperative chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, docetaxel) in locally advanced, resectable gastric and...

multiple myeloma

Understanding Risk Stratification in Monoclonal Gammopathy of Undetermined Significance

About 4 years ago, I [Jo Cavallo] wrote about the death of my brother Dom from multiple myeloma in 2011 and my subsequent enrollment in the PROMISE trial (ClinicalTrials.gov identifier NCT03689595). My goal for enrolling in the study was twofold: to honor Dom and others with the cancer and to make ...

breast cancer

Enobosarm in Previously Treated Patients With AR-Positive, ER-Positive, HER2-Negative Advanced Breast Cancer

In a phase II trial (Study G200802) reported in The Lancet Oncology, Palmieri et al found that the novel selective androgen receptor (AR) modulator enobosarm was active in previously treated patients with AR-positive, estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic...

issues in oncology

NIH’s New Cancer Screening Research Network Could Help Determine Effective Cancer Screening Technologies

The National Institutes of Health (NIH) has launched the Cancer Screening Research Network, a clinical trials network to evaluate emerging cancer screening technologies. The new network will support the Biden-Harris Administration’s Cancer Moonshot initiative by investigating how to identify cancer ...

Advertisement

Advertisement




Advertisement